Subcutaneous continuous erythropoietin receptor activator conversion provides practical advantages and potential convenience for peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 31, Issue 5, 2011, Pages 592-595

  Chen, Chun Yu ^a,b   Hsu, Heng Jung ^a,b   Lin, Yu Ying ^b   Wu, Mai Szu ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Anemia; CERA; Darbepoetin; Epoetin; Hemoglobin

Indexed keywords

ANTIHYPERTENSIVE AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN BETA; UNCLASSIFIED DRUG;

ADULT; ANEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT DURATION;

ADULT; AGED; ANEMIA; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES;

EID: 84862962918     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/PDI.2011.00013     Document Type: Short Survey

References (10)

1. Lo WK. Latest strategy in renal anemia management in peritoneal dialysis patients. Perit Dial Int 2008; 28(Suppl 3):S76-80.
2. Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, et al. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007; 370:1415-21.
3. Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant 2010; 25:4009-17.
4. Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty FC, et al. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study. Hemodial Int 2010; 14:233-9.
5. Fliser D, Kleophas W, Dellanna F, Winkler RE, Backs W, Kraatz U, et al. Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Curr Med Res Opin 2010; 26:1083-9.
6. Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phaseIII study. Nephrol Dial transplant 2008; 23:3654-61.
7. Dellanna F, Winkler RE, Bozkurt F, Schettler V, Graf S, Bockreiss N, et al. Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Int J Clin Pract 2011; 65:64-72.
8. Burkart J, Beswick R, Moran J. Hemoglobin levels in patients on peritoneal dialysis receiving CERA versus epoetin for anemia of chronic kidney disease (CKD): pooled analysis of two phaseIII trials (Abstract). Perit Dial Int 2007; 27(Suppl 3):S13.
9. Burkart J, Beswick R, Moran J. Safety and tolerability of CERA in chronic kidney disease (CKD) patients receiving peritoneal dialysis: pooled data from two phaseIII maintenance trials (Abstract). Perit Dial Int 2007; 27(Suppl 3):S13.
10. Lee CC, Sun CY, Wu MS. Long-term modality-related mortality analysis in incident dialysis patients. Perit Dial Int 2009; 29:182-90.